1.0NIBNhttps://nibn.co.ilVA1https://nibn.co.il/author/va1/rich600338<blockquote class="wp-embedded-content"><a href="https://nibn.co.il/applied-projects-pipeline/anti-psma-adc-nanobodies-for-therapy-and-imaging/">Anti-PSMA ADC Nanobodies for Therapy and Imaging</a></blockquote> <script type='text/javascript'> <!--//--><![CDATA[//><!-- /*! This file is auto-generated */ !function(c,d){"use strict";var e=!1,n=!1;if(d.querySelector)if(c.addEventListener)e=!0;if(c.wp=c.wp||{},!c.wp.receiveEmbedMessage)if(c.wp.receiveEmbedMessage=function(e){var t=e.data;if(t)if(t.secret||t.message||t.value)if(!/[^a-zA-Z0-9]/.test(t.secret)){for(var r,a,i,s=d.querySelectorAll('iframe[data-secret="'+t.secret+'"]'),n=d.querySelectorAll('blockquote[data-secret="'+t.secret+'"]'),o=0;o<n.length;o++)n[o].style.display="none";for(o=0;o<s.length;o++)if(r=s[o],e.source===r.contentWindow){if(r.removeAttribute("style"),"height"===t.message){if(1e3<(i=parseInt(t.value,10)))i=1e3;else if(~~i<200)i=200;r.height=i}if("link"===t.message)if(a=d.createElement("a"),i=d.createElement("a"),a.href=r.getAttribute("src"),i.href=t.value,i.host===a.host)if(d.activeElement===r)c.top.location.href=t.value}}},e)c.addEventListener("message",c.wp.receiveEmbedMessage,!1),d.addEventListener("DOMContentLoaded",t,!1),c.addEventListener("load",t,!1);function t(){if(!n){n=!0;for(var e,t,r=-1!==navigator.appVersion.indexOf("MSIE 10"),a=!!navigator.userAgent.match(/Trident.*rv:11\./),i=d.querySelectorAll("iframe.wp-embedded-content"),s=0;s<i.length;s++){if(!(e=i[s]).getAttribute("data-secret"))t=Math.random().toString(36).substr(2,10),e.src+="#?secret="+t,e.setAttribute("data-secret",t);if(r||a)(t=e.cloneNode(!0)).removeAttribute("security"),e.parentNode.replaceChild(t,e)}}}}(window,document); //--><!]]> </script><iframe sandbox="allow-scripts" security="restricted" src="https://nibn.co.il/applied-projects-pipeline/anti-psma-adc-nanobodies-for-therapy-and-imaging/embed/" width="600" height="338" title="“Anti-PSMA ADC Nanobodies for Therapy and Imaging” — NIBN" frameborder="0" marginwidth="0" marginheight="0" scrolling="no" class="wp-embedded-content"></iframe>https://nibn.co.il/wp-content/uploads/2018/10/appliedbiotechnology.png640290Introduction   While most prostate cancers (PCa) are curable if diagnosed and treated early, few patients will still progress to metastatic PCa (mPCa). The therapeutic landscape for mPCa has changed significantly over the past decade due to the discovery of tumour-associated target antigens that has given rise to the use of radioimmunotherapy (RIT). The most […]